Research graph
References from Bridging innate and adaptive immunity: A bispecific SIRPαD1-αPCSK9 fusion protein reprograms macrophages for durable tumor clearance. Local targets link to admitted publications; unresolved targets remain external evidence.
Tumor-associated macrophages
10.1016/j.cub.2020.01.031 · 2020 · External reference
Emerging phagocytosis checkpoints in cancer immunotherapy
10.1038/s41392-023-01365-z · 2023 · External reference
The CD47-SIRPalpha Immune Checkpoint
10.1016/j.immuni.2020.04.011 · 2020 · External reference
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
10.1016/j.cell.2009.05.046 · 2009 · External reference
Targeting the CD47/SIRPalpha pathway in malignancies: recent progress, difficulties and future perspectives
2024 · External reference
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPalpha pathway with high safety and preclinical efficacy for hematological and solid tumors
10.1186/s13045-025-01742-x · 2025 · External reference
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
10.1056/nejmoa1807315 · 2018 · External reference
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
10.1136/jitc-2022-005517 · 2022 · External reference
Targeting phagocytosis checkpoints for cancer immunotherapy
10.1038/s41568-025-00893-w · 2026 · External reference
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
10.1016/s1470-2045(21)00584-2 · 2021 · External reference
SIRPalpha-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPalpha signal pathway via blocking the “don't eat me” signal and activating the “eat me” signal
10.1186/s13045-022-01385-2 · 2022 · External reference
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
10.1073/pnas.1305569110 · 2013 · External reference
CD47/SIRPalpha axis: bridging innate and adaptive immunity
10.1136/jitc-2022-004589 · 2022 · External reference
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review
10.1136/jitc-2020-001408 · 2020 · External reference
Deciphering the role of CD47 in cancer immunotherapy
10.1016/j.jare.2023.10.009 · 2024 · External reference
Role of CD47 as a marker of self on red blood cells
10.1126/science.288.5473.2051 · 2000 · External reference
Targeting CD47 for cancer immunotherapy
10.1186/s13045-021-01197-w · 2021 · External reference
IgG4 anti-CD47: Erythrophagocytosis and potential transfusion complications
10.1111/trf.70111 · 2026 · External reference
Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody)
10.1111/imj.15934 · 2022 · External reference
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
10.1200/jco.18.02018 · 2019 · External reference
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
10.1200/jco.22.02604 · 2023 · External reference
Super-resolution microscopy unveils the nanoscale organization and self-limiting clustering of CD47 in human erythrocytes
10.1093/jmcb/mjae041 · 2025 · External reference
Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47)--major differences between mouse and man and implications for signaling
10.1016/j.bcmd.2006.01.012 · 2006 · External reference
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy
10.1038/s41591-019-0356-z · 2019 · External reference
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
10.1073/pnas.1121623109 · 2012 · External reference
Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPalpha Facilitate Apoptotic Cell Clearance by Macrophages
10.4049/jimmunol.1401719 · 2015 · External reference
A CD47 antibody with minimized erythrocyte and thrombocyte toxicities
10.3389/fonc.2025.1686180 · 2025 · External reference
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
10.1158/1078-0432.ccr-25-1826 · 2025 · External reference
TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties
10.1182/blood-2019-122793 · 2019 · External reference
CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge
10.32604/or.2025.071708 · 2025 · External reference
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
10.1016/j.apsb.2022.12.016 · 2023 · External reference
Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
10.3389/fimmu.2022.1027235 · 2022 · External reference
Antigen Cross-Presentation by Macrophages
10.3389/fimmu.2020.01276 · 2020 · External reference
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
10.1172/jci.insight.155022 · 2022 · External reference
Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages
10.1016/1074-7613(95)90067-5 · 1995 · External reference
Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity
10.1186/s13045-020-00989-w · 2020 · External reference
Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8(+) T cells
10.1002/cti2.70014 · 2024 · External reference
IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
10.1016/j.heliyon.2024.e39858 · 2024 · External reference
Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma
10.2217/imt-2022-0087 · 2023 · External reference
Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels
10.1038/nrendo.2012.254 · 2013 · External reference
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
10.1038/s41392-023-01690-3 · 2024 · External reference
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
10.1093/ehjcvp/pvad019 · 2023 · External reference
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
10.1038/s41586-020-2911-7 · 2020 · External reference
Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells
2022 · External reference
Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy
2024 · External reference
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
10.1136/jitc-2024-010565 · 2025 · External reference
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
10.1158/1078-0432.ccr-20-3706 · 2021 · External reference
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPalpha, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study
10.1186/s13045-024-01646-2 · 2024 · External reference
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
10.3324/haematol.2024.286208 · 2025 · External reference
The landscape overview of CD47-based immunotherapy for hematological malignancies
10.1186/s40364-023-00456-x · 2023 · External reference
Targeting CD47/SIRPalpha as a therapeutic strategy, where we are and where we are headed
10.1186/s40364-022-00373-5 · 2022 · External reference
CD47-SIRPalpha blocking-based immunotherapy: Current and prospective therapeutic strategies
10.1002/ctm2.943 · 2022 · External reference
Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas
10.1182/blood.2019001744 · 2019 · External reference
The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions
10.1016/j.ccell.2023.10.007 · 2023 · External reference
Protective and pathogenic functions of macrophage subsets
10.1038/nri3073 · 2011 · External reference
Transcriptional regulation of macrophage polarization: enabling diversity with identity
10.1038/nri3088 · 2011 · External reference
Diversity, Mechanisms, and Significance of Macrophage Plasticity
10.1146/annurev-pathmechdis-012418-012718 · 2020 · External reference
PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells
10.1080/08820139.2022.2027439 · 2022 · External reference
PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
10.1186/s13046-022-02477-0 · 2022 · External reference
